Patrick Gladding
North Shore Hospital
77 Papers
264 Citations
Patrick Gladding is an academic researcher from North Shore Hospital. The author has contributed to research in topics: Medicine & Clopidogrel. The author has an hindex of 17, co-authored 73 publications. Previous affiliations of Patrick Gladding include Auckland City Hospital & Cleveland Clinic.
Chat about Author
Papers
Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?
Gregory J. Wehner,Linyuan Jing,Christopher M. Haggerty,Jonathan D. Suever,Joseph B. Leader,Dustin N. Hartzel,H. Lester Kirchner,Joseph N A Manus,Nick James,Zina Ayar,Patrick Gladding,Christopher W. Good,John G.F. Cleland,Brandon K. Fornwalt +13 more
TL;DR: Deviation of LVEF from 60% to 65% is associated with poorer survival regardless of age, sex, or other relevant comorbidities such as heart failure.
Antiplatelet drug nonresponsiveness.
TL;DR: The background, mechanisms, and evidence in support of the clinical significance of nonresponders to antiplatelet agents appear to have an increased incidence of vascular events are reviewed.
56
Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
Patrick Gladding,Harvey D. White,J. Voss,John A. Ormiston,James T. Stewart,Peter Ruygrok,Badi Bvaldivia,Ruth Baak,Catherine White,Mark Webster +9 more
TL;DR: Increasing the dose of clopidogrel in patients with nonresponder polymorphisms can increase antiplatelet response and personalizing clopIDogrel dosing using pharmacogenomics may be an effective method of optimizing treatment.
56
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
Gerald F. Watts,Christian Schwabe,Russell S. Scott,Patrick Gladding,David R. Sullivan,John M. Baker,P. Clifton,James D. Hamilton,B D Given,Stacey Melquist,Rong Zhou,Ting-Hsi Chang,Javier San Martín,Daniel Gaudet,Ira Goldberg,Joshua W. Knowles,Robert A. Hegele,Christie M. Ballantyne +17 more
TL;DR: First-in-human results from five cohorts of healthy volunteers and individuals with hepatic steatosis show that RNA interference treatment targeting ANGPTL3 was well tolerated and led to reduction in triglycerides and non-HDL cholesterol.
47
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
TL;DR: Use of a genetic test to guide thienopyridine treatment in patients with ACS is a potentially cost-effective treatment strategy, especially for Maoris and Pacific Islanders, and has the potential to reduce ethnic health disparities that exist in New Zealand.
42